At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Adjuvant Therapy for Patients With Primary Uveal Melanoma With Genetic Imbalance
In Brief
A Phase 2 clinical trial evaluating recombinant interferon alfa-2b, dacarbazine, and 1 other intervention for Ciliary Body and Choroid Melanoma, Medium/Large Size and 3 related conditions. Completed, enrolled 38 participants across 1 site.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Recombinant interferon alfa-2b may interfere with the growth of tumor cells. Giving interferon alfa-2b together with dacarbazine may be an effective treatment for primary uveal melanoma. PURPOSE: This phase II trial is studying how well giving dacarbazine together with recombinant interferon alfa-2b works in treating patients with primary uveal melanoma with genetic imbalance.
Study Details
Timeline
Interventions
Given subcutaneously (SC) 3 times a week for 24 weeks
Given IV on days 1 and 29
Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up